Retraction Watch: “Widely covered paper on ranitidine-cancer link retracted.”
Carcinogenesis: “Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine.”
Carcinogenesis: “Retraction to: Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine.”
Organic Process Research and Development: “Ranitidine-Investigations into the Root Cause for the Presence of N-Nitroso-N,N-dimethylamine in Ranitidine Hydrochloride Drug Substances and Associated Drug Products.”
The Oncologist: “The Finding of N-Nitrosodimethylamine in Common Medicines.”
medRxiv: “Ranitidine use, N-Nitrosodimethylamine (NDMA)production and variations in cancer diagnoses.”
Statista.com: “Leading antacid tablet brands in the United States in 2019, based on sales (in million U.S. dollars).”
Ivan Oransky, MD, co-founder, Retraction Watch; Distinguished Writer in Residence, New York University.
David Light, CEO, Valisure, New Haven, CT.
Ron Najafi, PhD, president and CEO, Emery Pharma, San Francisco Bay area.
Brent Wisner, attorney, Baum Hedlund Aristei & Goldman, Los Angeles..
Jeremy Kahn, FDA spokesperson.
FDA: “Zantac (ranitidine): Safety Information—NDMA Found in Samples of Some Ranitidine Medicines.”
FDA: “Questions and Answers: NDMA Impurities in ranitidine (commonly known as Zantac).”
Joe Waechter, attorney, Morgan & Morgan.